MCL1 and ependymoma: For instance, in the MSKCC validation dataset, only 3 patients reported CN gain of MCL1. In contrast, MCL1 was relatively prevalent in roughly one-third of the entire cohort in this study, including 3 neuronal-glial tumors and 2 ependymoma.